Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 2/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002610 | 0.80 | ALDH1A1 (0.39) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL9038793 | 0.80 | ALDH1A1 (0.39) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL3952129 | 0.75 | CPN1 (0.46) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL13775379 | 0.74 | KMT2A (0.40) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1970713 | 0.74 | KMT2A (0.40) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL15546783 | 0.73 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL20215890 | 0.73 | CHRNB2 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL739703 | 0.73 | CHRNB2 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL10273099 | 0.73 | CHRNB2 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL8480027 | 0.72 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| EP-2233480-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| EP-2233480-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| EP-2086939-B8 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-2233480-A1 | Chemical compounds | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| EP-2086939-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | AstraZeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312372-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A1 1406/4885SLC6A11 793/4885TSHR 4092/4885 |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A1 1406/4885SLC6A11 793/4885TSHR 4092/4885 |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A1 1406/4885SLC6A11 793/4885TSHR 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.